PMID- 35836506 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220716 IS - 2219-6803 (Electronic) IS - 2218-676X (Print) IS - 2218-676X (Linking) VI - 11 IP - 6 DP - 2022 Jun TI - Comparison of efficacy and safety of bevacizumab biosimilar and original bevacizumab in non-squamous non-small cell lung cancer: a systematic review and meta-analysis. PG - 1472-1482 LID - 10.21037/tcr-22-71 [doi] AB - BACKGROUND: Bevacizumab (Avastin((R))), a monoclonal antibody targeting vascular endothelial growth factor (VEGF)-A, is widely used in treating a variety of malignant tumors. Several biosimilars of bevacizumab have been developed and marketed with the expiration of bevacizumab's patent. The objective of this study was to collate available data from head-to-head randomized controlled trials (RCTs) and evaluate the efficacy and safety of biosimilar bevacizumab compared with the bevacizumab (Avastin((R))) in patients with non-squamous non-small cell lung cancer (NSCLC). METHODS: Literature search of Web of Science, PubMed, Cochrane Library, EMBASE, and ClinicalTrials.gov was performed from inception until October 15, 2021. The efficacy outcome indicators were objective response rate (ORR), progression-free survival (PFS) and overall survival (OS). The occurrence of adverse events (AEs) was evaluated for safety outcome. RESULTS: Ten RCTs recruiting 6,416 patients with non-squamous NSCLC were included. All RCTs studies included the biosimilar bevacizumab group as the experimental group and the original bevacizumab group as the control group. The patients in the experimental group and control group received the same dose and duration of chemotherapy combined with carboplatin and paclitaxel. The results of meta-analysis showed that there were no significant differences in ORR [risk ratio (RR): 0.97, 95% confidence interval (95% CI): 0.93-1.02. P=0.841, I(2)=0], PFS (RR: 1.04, 95% CI: 0.98-1.10, P=0.235, I(2)=0) and OS (RR: 1.05, 95% CI: 1.00-1.10, P=0.692, I(2)=0) between the biomarker and original groups. The P values of ORR, PFS and OS were 0.533, 0.970 and 0.916 respectively as shown by Egger's test, suggesting that there was no publication bias. Subgroup analysis showed no significant differences in ORR, PFS, and OS between the Chinese and multicenter trials. The pooled incidence rate of AEs between two groups was similar, and there was also no significant difference between the two groups. DISCUSSION: This is the first study to independently report biosimilar bevacizumab in a meta-analysis on NSCLC treatment. The results showed that biosimilar bevacizumab had similar efficacy and safety compared with the original bevacizumab. TRIAL REGISTRATION: PROSPERO registration No. CRD42021276991. CI - 2022 Translational Cancer Research. All rights reserved. FAU - Xiao, Xian AU - Xiao X AD - Department of Oncology, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, China. AD - National Clinical Research Center for Chinese Medicine Acupuncture and Moxibustion, Tianjin, China. AD - Graduate School, Tianjin University of Traditional Chinese Medicine, Tianjin, China. FAU - Zhang, Guixing AU - Zhang G AD - Department of Oncology, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, China. AD - National Clinical Research Center for Chinese Medicine Acupuncture and Moxibustion, Tianjin, China. AD - Graduate School, Tianjin University of Traditional Chinese Medicine, Tianjin, China. FAU - Sun, Binxu AU - Sun B AD - Department of Oncology, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, China. AD - National Clinical Research Center for Chinese Medicine Acupuncture and Moxibustion, Tianjin, China. FAU - Wang, Chaoran AU - Wang C AD - Department of Oncology, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, China. AD - National Clinical Research Center for Chinese Medicine Acupuncture and Moxibustion, Tianjin, China. AD - Graduate School, Tianjin University of Traditional Chinese Medicine, Tianjin, China. FAU - Wang, Xiaoqun AU - Wang X AD - Department of Oncology, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, China. AD - National Clinical Research Center for Chinese Medicine Acupuncture and Moxibustion, Tianjin, China. FAU - Kong, Fanming AU - Kong F AD - Department of Oncology, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, China. AD - National Clinical Research Center for Chinese Medicine Acupuncture and Moxibustion, Tianjin, China. FAU - Jia, Yingjie AU - Jia Y AD - Department of Oncology, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, China. AD - National Clinical Research Center for Chinese Medicine Acupuncture and Moxibustion, Tianjin, China. LA - eng PT - Journal Article PL - China TA - Transl Cancer Res JT - Translational cancer research JID - 101585958 PMC - PMC9273685 OTO - NOTNLM OT - Bevacizumab OT - biosimilar OT - meta-analysis OT - non-squamous non-small cell lung cancer (non-squamous NSCLC) OT - randomized controlled trial (RCT) COIS- Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://tcr.amegroups.com/article/view/10.21037/tcr-22-71/coif). The authors have no conflicts of interest to declare. EDAT- 2022/07/16 06:00 MHDA- 2022/07/16 06:01 PMCR- 2022/06/01 CRDT- 2022/07/15 02:25 PHST- 2022/01/10 00:00 [received] PHST- 2022/04/12 00:00 [accepted] PHST- 2022/07/15 02:25 [entrez] PHST- 2022/07/16 06:00 [pubmed] PHST- 2022/07/16 06:01 [medline] PHST- 2022/06/01 00:00 [pmc-release] AID - tcr-11-06-1472 [pii] AID - 10.21037/tcr-22-71 [doi] PST - ppublish SO - Transl Cancer Res. 2022 Jun;11(6):1472-1482. doi: 10.21037/tcr-22-71.